The present application discloses compounds as inhibitors of the interaction between MDM2 and p53, pharmaceutical compounds containing such compounds, compounds used as drugs, in particular preparations for the treatment and / or prevention of tumor diseases and compounds for the synthesis of intermediates. 1. Claim 1: a compound characterized by formula (1),Where R1 is a selective population by one or more r7495；； 1 and / or r7580801；,identical or different, selected from C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, C₄₋₇ cycloalkenyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl and heterocyclyl of 3 to 10 members； each Rᵇ¹ is independently selected from -ORᶜ¹,-7580； - 7580； - 1,Halogen, - CN, - C (o) r7580；； 1-C (O) OR-C (O) NR R-S (O) R-S (O) NR R-NHC (O) R-N (C₁₋₄ alkyl) C (O) Rᶜ¹ and the bivalent substituent = O, while = O can only be a substituent on non-aromatic ring systems； each Rᶜ¹,Independent of each other,1. Represents hydrogen or one or more r7496； 1 and / or r7497； 1 can be selected,identical or different, selected from C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, C₄₋₇ cycloalkenyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl and heterocyclyl of 3 to 10 members； each Rᵈ¹ is independently selected from -ORᵉ¹,-No. 749781； - No. 749771； - 1,Halogen, - CN, - C (o) r7497；； 1-C (O) OR-C (O) NR R-S (O) R-S (O) NR R-NHC (O) R-N (C₁₋₄ alkyl) C (O) Rᵉ¹ and the bivalent substituent = O, while = O can only be a substituent on non-aromatic ring systems； each Rᵉ¹,Independent of each other,Indicates hydrogen or one or more r7584 can be selected；]identical or different, selected from C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, C₄₋₇ cycloalkenyl, C₆₋₁₀ aryl, 5- to 10-membered heteroaryl and heterocyclyl of 3 to 10 members； each Rᶠ¹ is independently selected from -ORᵍ¹,-7501； - 750101； - 1,Halogen, - CN, - C (o) r7501；； 1,-C (O) OR-C (O) NR R-S (O) R-S (O) NR R-NHC (O) R-N (C₁₋₄ alkyl) C (O) R
